Buchumschlag

Spleen volume reduction and transfusion independence with momelotinib versus ruxolitinib and associated overall survival with momelotinib in JAK inhibitor-naive patients with myelofibrosis and anemia: subgroup analyses of SIMPLIFY-1

Introduction - Improvements in splenomegaly, anemia, and overall survival (OS) are key considerations in the management of patients with myelofibrosis. In the phase III SIMPLIFY-1 trial (NCT01969838), momelotinib was noninferior to ruxolitinib for spleen volume reduction ≥ 35% (SVR35) and nominally...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Palandri, Francesca (Verfasst von) , Schaap, Nicolaas P. M. (Verfasst von) , Rey, Jerome (Verfasst von) , von Bubnoff, Nikolas (Verfasst von) , Reiter, Andreas (Verfasst von) , Hernandez-Boluda, Juan Carlos (Verfasst von) , Devos, Timothy (Verfasst von) , Nilsson, Lars (Verfasst von) , Psaila, Bethan (Verfasst von) , McLornan, Donal P. (Verfasst von) , Strouse, Bryan (Verfasst von) , Zhang, Shiyuan (Verfasst von) , Patel, Bharat (Verfasst von) , Lim, Jessica (Verfasst von) , Patnaik, Dwaipayan (Verfasst von) , Oh, Stephen T. (Verfasst von)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: May 2026
In: Clinical lymphoma, myeloma & leukemia
Year: 2026, Jahrgang: 26, Heft: 5, Pages: 297-308.e1
ISSN:2152-2669
DOI:10.1016/j.clml.2026.02.004
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.clml.2026.02.004
Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S215226502600039X
Volltext
Verfasserangaben:Francesca Palandri, Nicolaas P.M. Schaap, Jerome Rey, Nikolas von Bubnoff, Andreas Reiter, Juan Carlos Hernandez-Boluda, Timothy Devos, Lars Nilsson, Bethan Psaila, Donal P. McLornan, Bryan Strouse, Shiyuan Zhang, Bharat Patel, Jessica Lim, Dwaipayan Patnaik, Stephen T. Oh
Beschreibung
Zusammenfassung:Introduction - Improvements in splenomegaly, anemia, and overall survival (OS) are key considerations in the management of patients with myelofibrosis. In the phase III SIMPLIFY-1 trial (NCT01969838), momelotinib was noninferior to ruxolitinib for spleen volume reduction ≥ 35% (SVR35) and nominally superior for transfusion independence (TI) at week 24 in Janus kinase (JAK) inhibitor-naive patients. However, the relative impact of these endpoints on OS in anemic patients has not been described. - Materials and Methods - The present post hoc analysis evaluated week 24 SVR35, TI, and dual responses (SVR35 + TI) in patients with baseline hemoglobin < 10 g/dL. - Results - SVR35 rates were similar overall with momelotinib versus ruxolitinib (27/86 [31%] vs. 31/94 [33%]), but higher with momelotinib in the baseline platelets < 200 × 109/L subgroup (19/49 [39%] vs. 8/47 [17%]) and with ruxolitinib in the baseline platelets ≥ 200 × 109/L subgroup (8/37 [22%] vs. 23/47 [49%]). Week 24 SVR35 + TI was also more common with momelotinib (23/86 [27%]) than with ruxolitinib (7/94 [7%]). Subsequent OS analysis focused on the momelotinib arm only, as the crossover trial design precluded analysis of long-term OS with ruxolitinib. OS was longer in patients who were transfusion independent and/or achieved SVR35 at week 24 versus those who met neither endpoint (TI alone: n = 17, hazard ratio [HR], 0.25 [95% CI, 0.09-0.70]; SVR35 + TI: n = 23, HR, 0.40 [95% CI, 0.18-0.87]). - Conclusion - These results highlight that both spleen- and anemia-related benefits of momelotinib correlate with improved OS, supporting prioritization of TI in anemic patients for optimal long-term outcomes, and suggest that momelotinib may be the preferred JAK inhibitor in anemic patients with platelets < 200 × 109/L.
Beschreibung:Online verfügbar: 14. Februar 2026, Artikelversion: 6. Mai 2026
Gesehen am 07.07.2026
Beschreibung:Online Resource
ISSN:2152-2669
DOI:10.1016/j.clml.2026.02.004

Ähnliche Einträge